Anthony Sharratt’s Post

The U.S. public markets provide a great opportunity for U.K. biotech companies to gather funding and stake their pace in the industry. There are procedural barriers complicating this international IPO process, however. So, what does your business need to do to cross the Atlantic? Let our experts explain: https://bit.ly/450kZHp #CFGI #UK #UnitedKingdom #BioTech #IPO #GoingPublic #PublicReadiness

Preparing for an initial public offering in a complex field like life sciences can be intimidating, but with the right approach, you can get through it unscathed. There are simple yet important best practices that can help your business navigate IPO prep and earn your listing. Read our eBook for a step-by-step guide to life sciences and biotechnology IPOs: https://bit.ly/3ENmVIU #CFGI #LifeSciences #IPO #GoingPublic #PublicReadiness #Biotech

Our Q2 2024 Market Conditions Report highlights how there has been a substantial improvement in both the private and public biotech capital markets in H1 2024, with total deal value surpassing the total value for the entire year of 2023. However, the public markets remain challenging for earlier stage companies, and the IPO window remains largely closed, favoring later-stage companies with robust data and insider support. Download Locust Walk’s Q2 2024 Market Conditions Report to learn more about the biopharma landscapes: https://lnkd.in/eZuFcVpG

CFGI’s life sciences experts understand the nuances and requirements facing companies going public, anticipating potential hurdles from the outset.

A biotech IPO is a challenging but important step. Crossing national borders while undergoing this process adds even more complexity. It's possible to navigate these complications, however, when CFGI steps in. We can help U.K. life sciences companies go public on the U.S. market to better realize their potential. How does the process work, and might it be the right fit for you? Read our eBook to learn more: https://bit.ly/450kZHp #CFGI #GoingPublic #IPO #UnitedKingdom #Biotech #Biotechnology

Septerna Inc. Shares Jump 19% After Successful $288 Million IPO https://lnkd.in/dNSa4Ej5 Septerna Inc. shares surged 19% in their trading debut today after the biotechnology company raised $288 million in a larger-than-expected initial public offering. This strong performance reflects investor confidence in the company’s potential and growth prospects. #Biotechnology #InvestmentOpportunities #investorsentiment #IPO #SepternaInc #StockMarket #tradingdebut

Going public in an overseas market can help a company unlock new financial opportunities, but it's also complex, especially in heavily regulated industries like biotech. So, how did a U.K. biotechnology business cross the pond to launch its IPO in the U.S.? It took a little advisory assistance from CFGI's experts. Read the whole story in our eBook: https://bit.ly/450kZHp #CFGI #GoingPublic #IPO #UnitedKingdom #Biotech #Biotechnology

#knowledgeatthecenter In biotech, small ideas can have a big impact, but scaling them often requires a boost. Mergers and acquisitions act like a shot of steroids, helping pharma giants bulk up innovation quickly. But are these deals truly accelerating breakthroughs, or just inflating growth without substance? As more big players snap up small innovators, the industry must ask: are we building something sustainable, or just bulking up for the short term? #heretohealth #theGenH #MergersAndAcquisitions #Biotech #Pharma

Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead. #Biotech

Catch up on the latest transactions with our Diagnostics and Tools BlueBook, designed to provide valuable perspectives for industry leaders and private equity professionals. Discover a monthly executive review that captures the essence of valuation trends, M&A developments, and transactions. Key highlights from the July 2024 edition include: 📌Eurobio Scientific was acquired by MBK Partners 📌Astorg announced its acquisition of Hamilton Thorne 📌CytoReason closed a $80MM Series A Financing, led by NVDIA Corporation, Thermo Fisher Scientific, Pfizer Inc, OurCrowd Ltd Want to read more? https://hubs.li/Q02PpSLz0 #InvestmentBanking #MergersAndAcquisitions #LifeSciences #PrivateEquity